-Deccan Chronicle Prime Minister Narendra Modi may be patting himself on the back because President Barack Obama has agreed to India's position on food stockholding norms in World Trade Organisation (WTO). However, New Delhi seems to be bending over backwards to accommodate the American government and giant multinational corporations (MNCs) in the pharmaceutical industry, which will work to the detriment of our country's interests. In less than six months, the Modi government...

-The Indian Express It took the National Biodiversity Authority (NBA) six years, 18 drafts and a prod from the National Green Tribunal (NGT) to finalise the Guidelines for Access and Benefit Sharing (ABS) this August. Three months on, it is yet to notify the rules that would allow it to collect from domestic and foreign companies 0.1-1 per cent of their ex-factory gross sales of products using biological resources and traditional...

-The Times of India NEW DELHI: India registered the third highest rate for patent filings by non-residents at 78% of the total applications, ahead of China at 18%, Japan at 16% and the US at 50%, the latest data from the Indian patent office showed. Canada and Brazil topped the list with 86.6% and 84%, respectively. Officials opine this is an indicator of lack of awareness amongst the domestic industry as well...

-The Times of India NEW DELHI: The government's efforts to promote 'khadi' are facing a trademark hurdle with the brand having been registered abroad, in countries such as Germany, as well as in India. After haldi and basmati, this is the latest instance of infringement of Intellectual Property Rights, which is essentially traditional knowledge. What makes the task more difficult for the government is that 'khaddar' and 'khadi' are common across the...

-The Indian Express The era of globalised markets is also an era of globalised sovereignties. Nation states must constantly sync their policies with global constituencies of policies and citizens. At times, domestic disharmony is the price nation states may be required and willing to pay. The case in point here is the proposed review of the Intellectual Property Rights (IPR) policy, particularly those clauses that are related to pharmaceutical patent policy....